New Developments in Anti-Platelet Therapies Potential Use of CD39/Vascular ATP Diphosphohydrolase in Thrombotic Disorders

Author(s): Imrana Qawi, Simon C. Robson

Journal Name: Current Drug Targets

Volume 1 , Issue 3 , 2000

Become EABM
Become Reviewer
Call for Editor


Abnormal platelet reactivity has been linked to unstable angina, myocardial infarction, post angioplasty stenosis, cerebral ischemia, thrombotic stroke and a variety of inflammatory vascular disorders associated with transplantation. Drugs that inhibit blood coagulation, promote fibrinolysis or block platelet activation are important therapeutic agents in cardiovascular medicine. However, many of the current antiplatelet modalities are nonspecific, ineffective or associated with severe side effects that limit their usefulness. In this article, we discuss some basic aspects of platelet pathophysiology to illustrate the importance of ADP stimulation and signaling in platelet activation. CD39, the ATP diphosphohydrolase (ATPDase) expressed on quiescent vascular endothelium, modulates platelet purinoreceptor activity by the sequential hydrolysis of extracellular ATP or ADP directly to AMP. This thromboregulatory potential of CD39 has been recently demonstrated by the generation of mutant mice with disruption of the gene, and by a series of experiments where high level ATPDase expression has been attained by adenoviral vectors in the injured vasculature. Systemic administration of soluble derivatives of CD39 or targeted expression of the native protein to sites of vascular injury may have future therapeutic application.

Keywords: Anti-Platelet Therapies, CD39/Vascular ATP Diphosphohydrolase, Thrombotic Disorders, CD39, Hemostasis, Platelets, Integrins, Vascular Throm Bosis, Antiplatelet drugs

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2000
Page: [285 - 296]
Pages: 12
DOI: 10.2174/1389450003349173
Price: $65

Article Metrics

PDF: 5